Mepivacaina Recordati

Mepivacaine, the active ingredient in Mepivacaina Recordati, is a local anesthetic presented as a sterile solution for epidural, infiltration and perineural administration. It provides reversible nerve block for surgical, dental and obstetric procedures in adult patients and is commonly employed in outpatient settings.

GNH USA supplies Mepivacaina Recordati as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides full regulatory documentation to support import, distribution and clinical use across multiple regions.

Mepivacaine is used as a local anesthetic for regional pain control in various clinical settings.

Epidural analgesia: provides regional pain relief during labor, childbirth or postoperative recovery. Infiltration anesthesia: produces localized numbness for minor surgical or dental procedures. Peripheral nerve block: enables targeted anesthesia of specific nerve territories for orthopedic or trauma surgery. Dental procedures: facilitates painless tooth extractions, restorations and periodontal surgery. Surgical anesthesia: contributes to general anesthesia regimens by providing supplemental local analgesia.

Adverse reactions to mepivacaine are generally related to its local anaesthetic properties or systemic absorption.

Common Side Effects: - Transient numbness at injection site - Mild tingling or paresthesia - Local swelling or erythema

Serious or Rare Side Effects: - Cardiac arrhythmias, including ventricular tachycardia - Seizures due to central nervous system toxicity - Severe allergic reactions (anaphylaxis)

When using mepivacaine, clinicians should observe several precautionary measures to minimise risk.

Allergy assessment: verify no hypersensitivity to amide‑type local anesthetics Cardiovascular monitoring: observe for arrhythmias in patients with cardiac disease Dose adjustment: consider reduced dose in elderly or patients with hepatic impairment Concurrent CNS depressants: use caution when combined with other central nervous system depressants Store at ambient temperature: keep in original container, protect from light and moisture

Mepivacaine may interact with other medicines, altering its toxicity or efficacy.

Major Interactions (Avoid): - Class I antiarrhythmic agents (e.g., quinidine, procainamide): increase risk of systemic toxicity - Beta‑blockers: may potentiate bradycardia and hypotension

Moderate Interactions (Monitor Closely): - Monoamine oxidase inhibitors: can enhance central nervous system effects - Tricyclic antidepressants: may increase risk of seizures - Other local anesthetics: additive toxicity when used concurrently - CNS depressants (e.g., opioids, benzodiazepines): may deepen sedation